Therapeutic activity and biodistribution of a nano-sized
polymer-dexamethasone conjugate intended for the targeted
treatment of rheumatoid arthritis

J 2024

Therapeutic activity and biodistribution of a nano-sized polymer-dexamethasone conjugate intended for the targeted treatment of rheumatoid arthritis

RUBANOVÁ, Daniela, Svitlana SKOROPLYAS, Alena LIBANSKA, Eva RANDAROVA, Josef BRYJA et. al.

Basic information

Original name

Therapeutic activity and biodistribution of a nano-sized polymer-dexamethasone conjugate intended for the targeted treatment of rheumatoid arthritis

Authors

RUBANOVÁ, Daniela (203 Czech Republic, belonging to the institution), Svitlana SKOROPLYAS (804 Ukraine, belonging to the institution), Alena LIBANSKA, Eva RANDAROVA, Josef BRYJA (203 Czech Republic, belonging to the institution), Michaela CHORVÁTOVÁ (703 Slovakia, belonging to the institution), Tomas ETRYCH and Lukas KUBALA

Edition

Nanomedicine: Nanotechnology, Biology and Medicine, Elsevier, 2024, 1549-9634

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30226 Rheumatology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.400 in 2022

Organization unit

Faculty of Science

DOI

http://dx.doi.org/10.1016/j.nano.2023.102716

UT WoS

001110181400001

Keywords in English

Dexamethasone; Rheumatoid arthritis; HPMA; RANKL; Biodistribution

Abstract

V originále

Rheumatoid arthritis is a chronic inflammatory autoimmune disease caused by alteration of the immune system. Current therapies have several limitations and the use of nanomedicines represents a promising strategy to overcome them. By employing a mouse model of adjuvant induced arthritis, we aimed to evaluate the bio-distribution and therapeutic effects of glucocorticoid dexamethasone conjugated to a nanocarrier based on biocompatible N-(2-hydroxypropyl) methacrylamide copolymers. We observed an increased accumulation of dexamethasone polymer nanomedicines in the arthritic mouse paw using non-invasive fluorescent in vivo im-aging and confirmed it by the analysis of tissue homogenates. The dexamethasone conjugate exhibited a dose-dependent healing effect on arthritis and an improved therapeutic outcome compared to free dexamethasone. Particularly, significant reduction of accumulation of RA mediator RANKL was observed. Overall, our data suggest that the conjugation of dexamethasone to a polymer nanocarrier by means of stimuli-sensitive spacer is suitable strategy for improving rheumatoid arthritis therapy.

Citovat

RUBANOVÁ, Daniela, Svitlana SKOROPLYAS, Alena LIBANSKA, Eva RANDAROVA, Josef BRYJA, Michaela CHORVÁTOVÁ, Tomas ETRYCH and Lukas KUBALA. Therapeutic activity and biodistribution of a nano-sized polymer-dexamethasone conjugate intended for the targeted treatment of rheumatoid arthritis. Nanomedicine: Nanotechnology, Biology and Medicine. Elsevier, 2024, vol. 55, January, p. 1-10. ISSN 1549-9634. Available from: https://dx.doi.org/10.1016/j.nano.2023.102716.

@article{2368110,
   author = {Rubanová, Daniela and Skoroplyas, Svitlana and Libanska, Alena and Randarova, Eva and Bryja, Josef and Chorvátová, Michaela and Etrych, Tomas and Kubala, Lukas},
   article_number = {January},
   doi = {http://dx.doi.org/10.1016/j.nano.2023.102716},
   keywords = {Dexamethasone; Rheumatoid arthritis; HPMA; RANKL; Biodistribution},
   language = {eng},
   issn = {1549-9634},
   journal = {Nanomedicine: Nanotechnology, Biology and Medicine},
   title = {Therapeutic activity and biodistribution of a nano-sized polymer-dexamethasone conjugate intended for the targeted treatment of rheumatoid arthritis},
   url = {https://www.sciencedirect.com/science/article/pii/S1549963423000679},
   volume = {55},
   year = {2024}
}

TY  - JOUR
ID  - 2368110
AU  - Rubanová, Daniela - Skoroplyas, Svitlana - Libanska, Alena - Randarova, Eva - Bryja, Josef - Chorvátová, Michaela - Etrych, Tomas - Kubala, Lukas
PY  - 2024
TI  - Therapeutic activity and biodistribution of a nano-sized polymer-dexamethasone conjugate intended for the targeted treatment of rheumatoid arthritis
JF  - Nanomedicine: Nanotechnology, Biology and Medicine
VL  - 55
IS  - January
SP  - 1-10
EP  - 1-10
PB  - Elsevier
SN  - 15499634
KW  - Dexamethasone
KW  - Rheumatoid arthritis
KW  - HPMA
KW  - RANKL
KW  - Biodistribution
UR  - https://www.sciencedirect.com/science/article/pii/S1549963423000679
N2  - Rheumatoid arthritis is a chronic inflammatory autoimmune disease caused by alteration of the immune system. Current therapies have several limitations and the use of nanomedicines represents a promising strategy to overcome them. By employing a mouse model of adjuvant induced arthritis, we aimed to evaluate the bio-distribution and therapeutic effects of glucocorticoid dexamethasone conjugated to a nanocarrier based on biocompatible N-(2-hydroxypropyl) methacrylamide copolymers. We observed an increased accumulation of dexamethasone polymer nanomedicines in the arthritic mouse paw using non-invasive fluorescent in vivo im-aging and confirmed it by the analysis of tissue homogenates. The dexamethasone conjugate exhibited a dose-dependent healing effect on arthritis and an improved therapeutic outcome compared to free dexamethasone. Particularly, significant reduction of accumulation of RA mediator RANKL was observed. Overall, our data suggest that the conjugation of dexamethasone to a polymer nanocarrier by means of stimuli-sensitive spacer is suitable strategy for improving rheumatoid arthritis therapy.
ER  -

RUBANOVÁ, Daniela, Svitlana SKOROPLYAS, Alena LIBANSKA, Eva RANDAROVA, Josef BRYJA, Michaela CHORVÁTOVÁ, Tomas ETRYCH and Lukas KUBALA. Therapeutic activity and biodistribution of a nano-sized polymer-dexamethasone conjugate intended for the targeted treatment of rheumatoid arthritis. \textit{Nanomedicine: Nanotechnology, Biology and Medicine}. Elsevier, 2024, vol.~55, January, p.~1-10. ISSN~1549-9634. Available from: https://dx.doi.org/10.1016/j.nano.2023.102716.

Detailed Information on Publication Record